 |
Parkinsons News: 273 headlines |
|
|||||
Celebrity Fight Night Video  |
||||||||
|
||||||||
|
||||||||
| Sources used by our Parkinsons News Channel Research Team: | ||||||||
| The New York Times, CNN, FOX, CBS, BBC, Mayo Clinic, Johns Hopkins Medicine, UCLA Medical Center, National Institute of Health, Stanford Hospital, Memorial Sloan- Kettering, Yale Cancer Center, Massachusetts General Hospital, Brigham and Women's Hospital, University of Michigan, M. D. Anderson Cancer Center, National Institute of Health, American Cancer Association, NBC, Reuters News, American College of Cardiology, Journal of the American Medical Association & 100's more | ||||||||
| Links | ||||||||
| Barrow Neurological Institute | ||||||||
| Archives |
Thursday
ICPDMD: Long-Acting Ropinirole Eases Parkinson's Sleep Symptoms
PARIS, June 10 -- A new once-a-day formulation of ropinirole eases nighttime symptoms for Parkinson's disease patients, researchers here say.
Patients in two randomized controlled trials had an approximately 20% improvement in symptoms such as sleep disruption, cramping, nocturia, and confusion, according to lead author K. Ray Chaudhuri, M.D., of Kings College Hospital in London.
"Nocturnal symptoms are one of the most common complications of Parkinson's disease," Dr. Chaudhuri told attendees at the International Congress of Parkinson's Disease and Movement Disorders here. And these symptoms worsen as the disease progresses, he said.
Levodopa, the mainstay treatment for Parkinson's, usually controls these symptoms early in the disease. But effective duration of a single dose decreases as the disease progresses, so that by morning, advanced patients have little benefit from their last dose in the evening.
Dr. Chaudhuri and his colleagues tested the ability of prolonged release ropinirole (PRR) to address this problem in two large, phase III, 24-week clinical trials, one comparing PRR to placebo, and the other comparing it to standard ropinirole, given three times a day....full report in MedPage Today
Patients in two randomized controlled trials had an approximately 20% improvement in symptoms such as sleep disruption, cramping, nocturia, and confusion, according to lead author K. Ray Chaudhuri, M.D., of Kings College Hospital in London.
"Nocturnal symptoms are one of the most common complications of Parkinson's disease," Dr. Chaudhuri told attendees at the International Congress of Parkinson's Disease and Movement Disorders here. And these symptoms worsen as the disease progresses, he said.
Levodopa, the mainstay treatment for Parkinson's, usually controls these symptoms early in the disease. But effective duration of a single dose decreases as the disease progresses, so that by morning, advanced patients have little benefit from their last dose in the evening.
Dr. Chaudhuri and his colleagues tested the ability of prolonged release ropinirole (PRR) to address this problem in two large, phase III, 24-week clinical trials, one comparing PRR to placebo, and the other comparing it to standard ropinirole, given three times a day....full report in MedPage Today